Tag: #colon-cancer

Articles related to colon-cancer

health

NICHE‑2 phase 2 follow‑up: short‑course neoadjuvant immunotherapy linked to 100% 3‑year disease‑free survival in dMMR colon cancer

NICHE‑2 reports 100% 3‑year disease‑free survival after brief neoadjuvant ipilimumab+nivolumab for dMMR colon cancer; single‑arm results need confirmation.

#immunotherapy, #colon-cancer, #clinical-trial, #dmmr